| Robert Montgomery, MFT | |
|
6619 Dunbarton Dr, Tuscaloosa, AL 35406-2920 | |
| (205) 886-6619 | |
| Not Available |
| Full Name | Robert Montgomery |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 6619 Dunbarton Dr, Tuscaloosa, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902207376 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | A139 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert Montgomery, MFT 6619 Dunbarton Dr, Tuscaloosa, AL 35406-2920 Ph: (205) 886-6619 | Robert Montgomery, MFT 6619 Dunbarton Dr, Tuscaloosa, AL 35406-2920 Ph: (205) 886-6619 |
News Archive
Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.
UQ researchers have discovered a potential drug target for Alzheimer's disease — an enzyme which has effects on both the immune and nervous systems.
More than 100,000 cancers - equivalent to one third of all those diagnosed in the UK each year - are being caused by smoking, unhealthy diets, alcohol and excess weight, according to new research by Cancer Research UK.
bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that Tod Woolf, Ph.D., President and CEO, along with members of RXi's management team, will ring the Nasdaq closing bell tomorrow, Tuesday, Oct 6, 2009 at the Nasdaq Marketsite in New York City's Times Square.
› Verified 5 days ago
Dr. Brian M Monroe, PHD, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2810 8th St, Tuscaloosa, AL 35401 Phone: 205-632-0125 | |
Mrs. Susan Howell Goertz, M.S., LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2727 6th St, Tuscaloosa, AL 35401 Phone: 205-210-8099 Fax: 205-752-0590 | |
Mrs. Christie Wheat Gibson, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2720 7th St, Tuscaloosa, AL 35401 Phone: 205-210-8099 Fax: 205-248-2254 | |
Laura Mcnulty, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2810 8th St, Tuscaloosa, AL 35401 Phone: 205-239-3752 | |
Mrs. Jordan English Valentim, AMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2910 7th St, Tuscaloosa, AL 35401 Phone: 205-210-8099 | |
Dr. Karly Downs, PHD, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1107 23rd Ave, Tuscaloosa, AL 35401 Phone: 205-737-4764 | |
Mrs. Emily M Simpson-keenum, MFT, ASSOCIATE Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2910 7th St, Tuscaloosa, AL 35401 Phone: 205-210-8099 |